+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 21Years +
All Genders
ID06075810

Phase 1 Trial of Oral MBQ-167 for Advanced Breast Cancer Evaluating Dose and Safety

Led by MBQ Pharma · Updated on 2026-08-31

48

Participants Needed

4

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating MBQ-167, an oral drug, in a Phase 1 clinical trial for participants with advanced breast cancer who have not responded to or cannot tolerate standard treatments. The study aims to find the maximum tolerated dose, understand side effects, determine how the drug is processed in the body, and assess whether it can slow, stop, or eliminate cancer. Participants will take MBQ-167 capsules twice daily with meals, starting with doses ranging from 10mg to 400mg following a dose-escalation design. They will take the drug for at least 21 days and may continue if it is safe and effective. The study includes multiple visits for evaluations, laboratory tests, and diary reviews throughout treatment and after stopping the drug. During the trial, participants will provide informed consent and be monitored closely with physical exams and lab tests. Researchers will measure the maximum tolerated dose over 21 days and study drug levels and gene expression changes over up to 56 days. Safety and treatment effects will be tracked until the participant stops the drug or the study ends, with total participation lasting until December 2026 or earlier if discontinued.

CONDITIONS

Brief Title

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

Research Team

S

Scott Houston

J

Jose Rodriguez-Orengo, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here